PR Newswire Clinical TrialsOriginal article
Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research
Data ReadoutpositivesirexatamabPositive
AI Analysis
Summary
Leap Therapeutics announced publication of DeFianCe study results showing sirexatamab improved response, progression-free survival, and overall survival in DKK1-high second-line metastatic colorectal cancer patients when combined with bevacizumab, with DKK1 established as a predictive biomarker.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
DeFianCe study results published in Clinical Cancer Research showing sirexatamab improved response, progression-free survival, and overall survival in DKK1-high 2L mCRC patients when added to bevacizumab; DKK1 established as predictive biomarker
Importance:6/10
Sentiment:
0.70
publicationbiomarkercolorectal cancersirexatamabDKK1bevacizumab
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 12, 2026 11:00 AM